Methods of identifying reduced internalization transmembrane receptor agonists
View Patent ↗Described herein are methods of identifying a transmembrane receptor (TMR) agonist and compounds identified by this method. The TMR agonist (TMRA) is capable of activating TMR signaling while exhibiting reduced TMR internalization over a control compound.
1. A method of identifying a G protein-coupled receptor (GPCR) agonist, wherein the GPCR agonist is capable of activating GPCR signaling while exhibiting reduced GPCR internalization as compared to a control compound, comprising the steps of:
(a) providing a cell comprising at least one GPCR or a modified GPCR capable of activating intracellular signaling and an arrestin, or a fragment thereof capable of binding a GPCR,
(b) exposing the cell to at least one test compound,
(c) measuring GPCR signaling at two or more points in time,
(d) measuring internalization of the GPCR at two or more points in time,
(e) quantitatively determining if GPCR internalization is reduced by comparing GPCR internalization in the presence of the test compound to GPCR internalization in the presence of a control compound, and wherein-GPCR signaling is activated in the presence of the test compound as compared to GPCR signaling in the absence of the test compound,
(f) wherein a reduction in GPCR internalization in the presence of the test compound as compared to the control compound indicates the test compound is a GPCR agonist capable of activating GPCR signaling while exhibiting reduced GPCR internalization.
2. The method of claim 1 , wherein the internalization of the GPCR is measured by monitoring localization of a detectable molecule bound to the arrestin or to the GPCR.
3. The method of claim 1 , wherein signaling is quantitated by measuring an intracellular effector, wherein said effector is cAMP, cyclic GMP, calcium, a lipid, phosphatidylinositol, a hydrogen ion, or an ion transport molecule.
4. The method of claim 1 , wherein the signaling is activated for a longer time period after stimulation by the test compound than the length of time of activation after stimulation by the control compound.
5. The method of claim 1 , wherein the internalization of the GPCR is measured by determining the localization of the GPCR in the plasma membrane, pits, endosomes, endocytic vesicles, or cytosol.
6. The method of claim 1 , wherein the GPCR is a class A, or class B receptor.
7. The method of claim 1 , wherein the GPCR is a μ opioid, β 1 AR, β 2 AR, or dopamine receptor.
8. The method of claim 1 , wherein the internalization of the GPCR is measured by visualization of a radioisotope, an epirope tag, an affinity label, an enzyme, a fluorescent group, or a chemiluminescent group attached to the arrestin or the GPCR.
9. The method of claim 1 , wherein the signaling is measured at the same time as the internalization is measured.
10. The method of claim 1 , wherein the cell is exposed to the compound once, and wherein the cell is not exposed a second time to the compound.
11. The method of claim 1 , wherein the GPCR is a rat, mouse, pig, or primate GPCR.
12. The method of claim 1 , wherein the steps (a)-(f) are repeated, and wherein the GPCR used in the repeated steps is from a different species than ihe GPCR used in steps (a)(f).
13. The method of claim 12 , wherein a test compound that is used in steps (a)-(f) is not used in the repeated steps.
14. The method of claim 1 , wherein the test compound is from a combinatorial library.
15. The method of claim 1 , wherein the signaling in the presence of the test compound is equal to or greater than the signaling in the presence of the control compound.
16. The method of claim 1 , wherein the method is repeated at different concentrations of compound to yield a dose-response curve for the signaling measurement and a dose-response curve for the internalization measurement in the presence of the test compound.
17. The method of claim 16 , wherein the quantitative determination includes a comparison of the dose-response curve for the signaling measurement to the dose-response curve for the internalization measurement.
18. The method of claim 16 , wherein a second dose-response curve for the signaling measurement and a second dose-response curve for the internalization measurement are determined in the presence of control compound.
19. The method of claim 18 , wherein the dose-response curve for the internalization measurement in the presence of the test compound is less than the dose-response curve for the internalization measurement in the presence of the control compound.
20. The method of claim 18 , wherein the dose-response curve for the signaling measurement in the presence of the test compound is approximately equal to or greater than the dose-response curve for the signaling measurement in the presence of the control compound.
21. The method of claim 19 , wherein the reduced internalization is determined by a decrease in the Max of the dose-response curve for the internalization measurement in the presence of the test compound, as compared to the Max of the dose-response curve for the internalization measurement in the presence of the control compound.
22. The method of claim 19 , wherein the reduced internalization is determined by an increase in the EC50 of the dose-response curve for the internalization measurement in the presence of the test compound, as compared to the EC50 of the dose-response curve for the internalization measurement in the presence of the control compound.
23. A method of identifying a G protein-coupled receptor (GPCR) agonist, wherein the GPCR agonist is capable of activating GPCR signaling while exhibiting reduced GPCR internalization over a control compound, comprising the steps of:
(a) providing a cell comprising at least one GPCR or a modified GPCR capable of activating intracellular signaling and an arrestin, or a fragment thereof capable of binding a GPCR,
(b) exposing the cell to at least one test compound,
(c) measuring GPCR signaling at one or more concentration of the test compound,
(d) measuring internalization of the GPCR at one or more concentrations of the test compound,
(e) quantitatively determining if GPCR internalization is reduced by comparing GPCR internalization in the presence of the test compound to GPCR internalization in the presence of a control compound, and wherein GPCR signaling is activated in the presence of the test compound as compared to GPCR signaling in the absence of the test compound,
(f) wherein a reduction in GPCR internalization in the presence of the test compound as compared to the control compound indicates the test compound is a GPCR agonist capable of activating GPCR signaling while exhibiting reduced GPCR internalization.
24. The method of claim 23 , wherein the internalization of GPCR is measured by monitoring localization of a detectable molecule bound to the arrestin or the GPCR.
25. The method of claim 23 , wherein signaling is quantitated by measuring an intracellular effector, wherein said effector may be cAMP, cyclic GMP, calcium, a lipid, phosphatidylinositol, a hydrogen ion, or an ion transport molecule.
26. The method of claim 23 , wherein the signaling is activated for a longer time period after stimulation by the test compound than the length of time of activation after stimulation by the control compound.
27. The method of claim 23 , wherein the internalization of the GPCR is measured by determining the localization of the GPCR in the plasma membrane, pits, endosomes, endocytic vesicles, or cytosol.
28. The method of claim 23 , wherein the GPCR is a class A, or class B receptor.
29. The method of claim 23 , wherein the GPCR is a μ opioid, β 1 AR, β 2 AR, or dopamine receptor.
30. The method of claim 23 , wherein the internalization of the GPCR is measured by visualization of a radioisotope, an epitope tag, an affinity label, an enzyme, a fluorescent group, or a chemiluminescent group attached to the arrestin or the GPCR.
31. The method of claim 23 , wherein the signaling is measured at the same time as the internalization is measured.
32. The method of claim 23 , wherein the cell is exposed to the compound once, and wherein the cell is not exposed a second time to the compound.
33. The method of claim 23 , wherein the GPCR is a rat, mouse, pig, or primate GPCR.
34. The method of claim 23 , wherein the steps (a)-(f) are repeated, and wherein the GPCR used in the repeated steps is from a different species than the GPCR used in steps (a)-(f).
35. The method of claim 34 , wherein a test compound that is used in steps (a)-(f) is not used in the repeated steps.
36. The method of claim 23 , wherein the rest compound is from a combinatorial library.
37. The method of claim 23 , wherein the signaling in the presence of the test compound is approximately equal to or greater than the signaling in the presence of the control compound.
38. The method of claim 23 , wherein the method is repeated at different concentrations of compound to yield a dose-response curve for the signaling measurement and a dose-response curve for the internalization measurements in the presence of the test compound.
39. The method of claim 38 , wherein the quantitative determination includes a comparison of the dose-response curve for the signaling measurement to the dose-response curve for the internalization measurement.
40. The method of claim 38 , wherein a second dose-response curve for the signaling measurement and a second dose-response curve for the internalization measurement are determined in the presence of control compound.
41. The method of claim 40 , wherein the dose-response curve for the internalization measurement in the presence of the test compound is less than the dose-response curve for the internalization measurement in the presence of, the control compound.
42. The method of claim 40 , wherein the dose-response curve for the signaling measurement in the presence of the test compound is approximately equal to or greater than the dose-response curve for the signaling measurement in the presence of the control compound.
43. The method of claim 41 , wherein the reduced internalization is determined by a decrease in the Max of the dose-response curve for the internalization measurement in the presence of the test compound, as compared to the Max of the dose-response curve for the internalization measurement in the presence of the control compound.
44. The method of claim 41 , wherein the reduced internalization is determined by an increase in the EC50 of the dose-response curve for the internalization measurement in the presence of the test compound, as compared to the EC50 of the dose-response curve for the internalization measurement in the presence of the control compound.
45. The method of claim 11 , wherein the primate GPCR is a human GPCR.
46. The method of claim 33 , wherein the primate GPCR is a human GPCR.